Cargando…

Survival of Patients with Thyroid Cancer in Yazd, Iran

BACKGROUND: Thyroid cancer is the most common endocrine related malignancy in the world. This cancer has increased during recent years in Iran and is the11th most common malignancy in Iranian population. Survival of patients with thyroid carcinoma in the different geographic areas within Iran is not...

Descripción completa

Detalles Bibliográficos
Autores principales: Ardakani, Hassan Ali Vahedian, Moghimi, Mansour, Shayestehpour, Mohammad, Doosti, Masoud, Sharifabadi, Shamsi Beigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697494/
https://www.ncbi.nlm.nih.gov/pubmed/28843269
http://dx.doi.org/10.22034/APJCP.2017.18.8.2293
_version_ 1783280635626913792
author Ardakani, Hassan Ali Vahedian
Moghimi, Mansour
Shayestehpour, Mohammad
Doosti, Masoud
Sharifabadi, Shamsi Beigi
author_facet Ardakani, Hassan Ali Vahedian
Moghimi, Mansour
Shayestehpour, Mohammad
Doosti, Masoud
Sharifabadi, Shamsi Beigi
author_sort Ardakani, Hassan Ali Vahedian
collection PubMed
description BACKGROUND: Thyroid cancer is the most common endocrine related malignancy in the world. This cancer has increased during recent years in Iran and is the11th most common malignancy in Iranian population. Survival of patients with thyroid carcinoma in the different geographic areas within Iran is not clear. The present study aimed to estimate survival of patients suffering from thyroid cancer in Yazd, Iran. METHODS: In this retrospective cohort study, data were collected from 80 patients with thyroid cancer registered in Shohadaye Kargar and Shahid Sadoughy hospitals in Yazd between March 2001 and March 2012. The Kaplan-Meier analysis was used for estimation of survival over time and Cox regression method was performed for calculating hazard ratios according to demographic and risk variables. RESULTS: Survival rates at the end of 1, 3, and 5 years in thyroid cancer patients were 99%, 96%, and 91%, respectively. A statistically significant correlation was found between stage of disease, type of cancer and survival time of patients (p<0.05). The worst survival was in peoples with the anaplastic type and stage IV of thyroid carcinoma. CONCLUSION: The survival of patients with thyroid carcinoma was higher than some areas in Iran. Since type and stage of thyroid cancer were the important factors in survival time, screening of people for cancer diagnosis in early stages, it seems to improve survival of patients. Radioactive iodine therapy can increase the survival rate in patients suffering from thyroid malignancy.
format Online
Article
Text
id pubmed-5697494
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-56974942017-12-01 Survival of Patients with Thyroid Cancer in Yazd, Iran Ardakani, Hassan Ali Vahedian Moghimi, Mansour Shayestehpour, Mohammad Doosti, Masoud Sharifabadi, Shamsi Beigi Asian Pac J Cancer Prev Research Article BACKGROUND: Thyroid cancer is the most common endocrine related malignancy in the world. This cancer has increased during recent years in Iran and is the11th most common malignancy in Iranian population. Survival of patients with thyroid carcinoma in the different geographic areas within Iran is not clear. The present study aimed to estimate survival of patients suffering from thyroid cancer in Yazd, Iran. METHODS: In this retrospective cohort study, data were collected from 80 patients with thyroid cancer registered in Shohadaye Kargar and Shahid Sadoughy hospitals in Yazd between March 2001 and March 2012. The Kaplan-Meier analysis was used for estimation of survival over time and Cox regression method was performed for calculating hazard ratios according to demographic and risk variables. RESULTS: Survival rates at the end of 1, 3, and 5 years in thyroid cancer patients were 99%, 96%, and 91%, respectively. A statistically significant correlation was found between stage of disease, type of cancer and survival time of patients (p<0.05). The worst survival was in peoples with the anaplastic type and stage IV of thyroid carcinoma. CONCLUSION: The survival of patients with thyroid carcinoma was higher than some areas in Iran. Since type and stage of thyroid cancer were the important factors in survival time, screening of people for cancer diagnosis in early stages, it seems to improve survival of patients. Radioactive iodine therapy can increase the survival rate in patients suffering from thyroid malignancy. West Asia Organization for Cancer Prevention 2017 /pmc/articles/PMC5697494/ /pubmed/28843269 http://dx.doi.org/10.22034/APJCP.2017.18.8.2293 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
Ardakani, Hassan Ali Vahedian
Moghimi, Mansour
Shayestehpour, Mohammad
Doosti, Masoud
Sharifabadi, Shamsi Beigi
Survival of Patients with Thyroid Cancer in Yazd, Iran
title Survival of Patients with Thyroid Cancer in Yazd, Iran
title_full Survival of Patients with Thyroid Cancer in Yazd, Iran
title_fullStr Survival of Patients with Thyroid Cancer in Yazd, Iran
title_full_unstemmed Survival of Patients with Thyroid Cancer in Yazd, Iran
title_short Survival of Patients with Thyroid Cancer in Yazd, Iran
title_sort survival of patients with thyroid cancer in yazd, iran
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697494/
https://www.ncbi.nlm.nih.gov/pubmed/28843269
http://dx.doi.org/10.22034/APJCP.2017.18.8.2293
work_keys_str_mv AT ardakanihassanalivahedian survivalofpatientswiththyroidcancerinyazdiran
AT moghimimansour survivalofpatientswiththyroidcancerinyazdiran
AT shayestehpourmohammad survivalofpatientswiththyroidcancerinyazdiran
AT doostimasoud survivalofpatientswiththyroidcancerinyazdiran
AT sharifabadishamsibeigi survivalofpatientswiththyroidcancerinyazdiran